As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the pharmaceutical and healthcare industry around the world to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2022 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that “every drug can be made and every disease can be treated.”

WuXi AppTec open-access platform enables customers worldwide to advance discoveries in the health sciences and deliver treatment to those in need. Our services include:

WuXi Chemistry | Integrated, end-to-end chemistry research, development, and commercial manufacturing services.
WuXi Biology | A full spectrum of biology-related services to support drug discovery and development.
WuXi Testing | Seamless drug and medical device testing services from preclinical testing to clinical trials.
WuXi Advanced Therapies | A Global Contract Testing Development and Manufacturing Organisation (CTDMO), offering an integrated end-to-end solution to accelerate time to market for cell and gene therapies.
WuXi STA | Efficient, flexible, and high-quality solutions for integrated CMC (Chemical, Manufacturing, and Controls) solutions from preclinical to commercial uses.
WuXi Tides | Integrated platform from discovery to drug product, coupled with comprehensive analytical support and CMC writing service.